Janus Henderson Group PLC Boosts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Janus Henderson Group PLC grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,516,831 shares of the pharmaceutical company’s stock after buying an additional 100,114 shares during the quarter. Vertex Pharmaceuticals accounts for 0.6% of Janus Henderson Group PLC’s portfolio, making the stock its 26th largest position. Janus Henderson Group PLC owned about 0.98% of Vertex Pharmaceuticals worth $1,170,506,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in VRTX. Harmony Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 12.7% during the 3rd quarter. Harmony Asset Management LLC now owns 6,917 shares of the pharmaceutical company’s stock valued at $3,217,000 after buying an additional 777 shares during the period. HighTower Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 7.6% during the third quarter. HighTower Advisors LLC now owns 57,242 shares of the pharmaceutical company’s stock valued at $26,494,000 after purchasing an additional 4,048 shares during the period. Hilltop Holdings Inc. boosted its stake in shares of Vertex Pharmaceuticals by 359.5% in the third quarter. Hilltop Holdings Inc. now owns 3,143 shares of the pharmaceutical company’s stock valued at $1,462,000 after purchasing an additional 2,459 shares during the period. Ascent Group LLC boosted its stake in shares of Vertex Pharmaceuticals by 19.5% in the third quarter. Ascent Group LLC now owns 10,796 shares of the pharmaceutical company’s stock valued at $5,021,000 after purchasing an additional 1,763 shares during the period. Finally, Beck Capital Management LLC grew its holdings in Vertex Pharmaceuticals by 1.9% during the 3rd quarter. Beck Capital Management LLC now owns 2,004 shares of the pharmaceutical company’s stock valued at $932,000 after purchasing an additional 38 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on VRTX shares. Bank of America dropped their price objective on Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating on the stock in a report on Monday, October 14th. Truist Financial reaffirmed a “buy” rating and issued a $550.00 price target (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. JPMorgan Chase & Co. decreased their price objective on shares of Vertex Pharmaceuticals from $510.00 to $503.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $600.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, October 21st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $504.38.

Vertex Pharmaceuticals Trading Down 0.5 %

Shares of Vertex Pharmaceuticals stock opened at $465.73 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $347.51 and a 1-year high of $519.88. The business’s fifty day moving average price is $472.87 and its two-hundred day moving average price is $475.06.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.67 earnings per share. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.